- Dow has selected an extract belonging to the DEINOVE proprietary strains’ bank to launch a new cosmetic active ingredient for skin care applications
- Commercialization is planned for early 2021
Deinove (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-based active ingredients for cosmetics and nutrition, announced a collaboration with Dow (NYSE: DOW) for the joint development of a cosmetic ingredient derived from its collection of bacterial extracts.
Deinove owns a large bacterial collection that today includes more than 6,000 rare strains, collected in many different biotopes (hot springs, volcanos, lagoons, beaches, caves…) and on various substrates (nearly 600 samples of wood, water, plant, sand,…).
Deinove has developed original and patented methods for the selection and culture of these rare bacteria. Several of these strains have been qualified via Deinove’s cell biology lab according to their properties on different cosmetic activities (anti-oxidant, anti-inflammatory, cell regeneration…).
Dow has selected one extract from Deinove’s bacterial bank. Deinove will now develop and optimize a dedicated production process and will ensure the industrial transposition and production of the developed cosmetic active. Leveraging its expertise and its cell biology laboratory in Belgium, Dow intends to qualify the cosmetic active and integrate it into its product portfolio, receiving commercial exclusivity worldwide.
Fabienne Bizeray, Dow’s Global Strategic Marketing Leader Skin & Sun Care: “We have chosen Deinove for its widely recognized expertise in biotechnology and valuation of rare microorganisms. After the launch of AgeCap Smooth™ in April 2018, this agreement will allow Dow to quickly develop a new natural cosmetic ingredient for our customers. This first collaboration with Deinove is perfectly aligned with our strategy of expanding and transforming our portfolio dedicated to skin care.”
“We are proud that a big industrial leader such as Dow has been convinced by our expertise and attracted by the richness of our bacterial collection. This agreement values the quality of our R&D approach and our portfolio of cosmetic actives.” adds Emmanuel Petiot, CEO of Deinove.